• Corpus ID: 9854986

Phase I trial and clinical pharmacology of elsamitrucin.

  title={Phase I trial and clinical pharmacology of elsamitrucin.},
  author={Martin N. Raber and Robert A Newman and B. M. Newman and Robert C. Gaver and Lee P. Schacter},
  journal={Cancer research},
  volume={52 6},
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a number of murine tumors including P388, L1210, B16 and M5076, as well as against MX1 and HCT116 xenografts. Preclinical toxicology studies of elsamitrucin revealed edema of multiple organs associated with hypoproteinemia and, at lethal doses, severe multiorgan toxicity. We conducted a phase I clinical trial (31 patients) of elsamitrucin administered as a 10-min i.v… 

Figures and Tables from this paper

An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
The MTD and recommended dose for Phase II trials of elsamitrucin is 0.08 mg/kg i.v. weekly, and this drug might be considered for combination protocols with myelosuppressive chemotherapy agents.
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
The activity of elsamitrucin in this group of patients and its lack of myelosuppression suggest utility in this disease especially when combined with other proven agents.
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.
  • J. Verweij, J. Wanders, S. Kaye
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 1994
Toxicity mainly consisted of mild nausea/vomiting, and less frequently reversible hepatotoxicity and malaise and Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer.
Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration
IT-622 showed an in vivo antitumor effect superior to that of authentic A-132, possibly resulting from a higher absorption ratio of IST- 622 through the gastrointestinal tract, and is under clinical phase I study in Japan.
In silico models for the prediction of dose-dependent human hepatotoxicity
A new, fully general in silico model is presented which is able to predict the occurrence of dose-dependent human hepatotoxicity with greater than 80% accuracy and is entirely appropriate for data mining applications and for profiling large synthetic and/or virtual libraries.
Methods to evaluate biliary excretion of drugs in humans: an updated review.
In addition to the determination of in vivo biliary clearance values of drugs, the availability of in vitro models that can predict the extent of biliary excretion of drugs in humans may be a powerful tool in the preclinical stages of drug development.
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
The need for alternative methods for conducting phase I trials is confirmed, baseline information against which alternatively conducted trials can be compared, and some practical clinical trial issues not generally considered are demonstrated.
Molecular dynamics study of the binding of elsamicin A to DNA.
Molecular mechanics and dynamics were used to examine the conformational flexibility of elsamicin A, an antitumour antibiotic, in aqueous solution and obtained the first three-dimensional model of the el samicin-A-DNA complex.
Induction of Decision Trees via Evolutionary Programming
This methodology is compared to single-tree and multiple-tree recursive partitioning in two domains (aerobic biodegradability and hepatotoxicity) and shown to produce less complex classifiers with average increases in predictive accuracy over the traditional method.


Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
New antitumor antibiotics, elsamicin A and B, were isolated from the culture broth of an unidentified actinomycete strain J907-21 (ATCC 39417) and were found to be 10-30 times more potent than that of chartreusin in terms of minimum effective dose.
  • H. Gaylord
  • Medicine
    California state journal of medicine
  • 1913
Transfusion and Serum Reaction in Carcinoma and Sarcoma and Observations on the Hemolytic Reactions of the Blood in Dogs Affected with Transplantable Lymphosarcoma.
Database Design and Management in a Pharmacokinetic Department
A system automating the flow of information from setting up a pharmacokinetics study through sample processing to pharmacokinetic data interpretation is described, which has resulted in a dramatic increase in sample throughput and decrease in the report preparation time.
Management of Pharmacokinetic Data Using HP-3357/Mainframe Ibm Interfacing
This computer system has greatly reduced the time necessary to analyze the data from a pharmacokinetic study and the reliability of the data is increased by eliminating data transposition errors and by forcing uniformity in sample processing.
An Approximate Test for Outliers in Linear Models
A test statistic for detecting outliers in linear models involving residuals standardized by their individual standard deviations is considered and it is suggested that its critical values are
The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. 1'har- macokinet
  • Biopharm
  • 1980
Bristol Myers Squibb Investigator's Brochure: Elsamitrucin
  • Bristol Myers Squibb Investigator's Brochure: Elsamitrucin
  • 1990
Identification and characterization of novel topoisomerase inhibitors
  • Proc. Am. Assoc. Cancer Res.,
  • 1988
HMY 28090 a new antitumor antibiotic related to chartreusin: isolation, chemistry and activity, Abstract 320
  • Abstracts of the 14th International Congress on Chemotherapy,
  • 1985
Statistical Methods, Ed
  • 1980